MARKET

VERU

VERU

VERU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.470
-0.040
-1.59%
After Hours: 2.470 0 0.00% 16:24 10/20 EDT
OPEN
2.510
PREV CLOSE
2.510
HIGH
2.530
LOW
2.460
VOLUME
123.03K
TURNOVER
--
52 WEEK HIGH
4.740
52 WEEK LOW
1.849
MARKET CAP
172.56M
P/E (TTM)
-15.8740
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Veru enrolls in Phase 2 trial for an oral drug for metastatic prostate cancer
Veru ([[VERU]] +2.7%) has fully enrolled its Phase 2 clinical study of VERU-111, its novel, oral, alpha and beta tubulin targeting drug for metastatic castration and novel androgen receptor targeting agent
Seekingalpha · 09/29 14:40
Veru Completes Enrollment Of Phase 2 Clinical Trial Of VERU-111, Novel Oral Drug For Metastatic Prostate Cancer
Veru Completes Enrollment of Phase 2 Clinical Trial of VERU-111, Novel Oral Drug for Metastatic Prostate Cancer MIAMI, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), an oncology and urology
Benzinga · 09/29 12:32
Veru Highlights Oral Presentation Of Resutls From VERU-111 Phase 1b Study In Metastatic Prostate Cancer At European Society for Medical Oncology Congress Sept. 19-21
Veru Inc. (NASDAQ:VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that positive clinical results from its Phase
Benzinga · 09/18 11:30
Veru Announces ESMO Congress 2020 Oral Presentation of Positive Clinical Results from its VERU-111 Phase 1b Study in Metastatic Prostate Cancer
—Advancing VERU-111 to a Pivotal Phase 3 Clinical Program—MIAMI, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that positive clinical results
GlobeNewswire · 09/18 11:30
Health Check: How Prudently Does Veru (NASDAQ:VERU) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Simply Wall St. · 09/17 19:55
The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference
Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market.
Benzinga · 09/13 13:49
Veru to Participate and Present at Four Upcoming Healthcare Investor Conferences
GlobeNewswire · 09/09 13:30
Insider Buys Veru's Stock
Veru Inc (NASDAQ:VERU) was trading 3.5% higher from the previous closing price. A Form 4 filing filed with the SEC on Tuesday, August 25 showed that and Greco Michele bought 5,000 shares at an average price of $2.65. The transaction moved the executive's stake in Veru Inc. to 96,178 shares.
Benzinga · 08/26 15:47
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VERU. Analyze the recent business situations of VERU through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VERU stock price target is 8.50 with a high estimate of 13.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 86
Institutional Holdings: 16.29M
% Owned: 23.31%
Shares Outstanding: 69.86M
TypeInstitutionsShares
Increased
23
5.24M
New
35
1.44M
Decreased
13
1.32M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
0.00%
Pharmaceuticals & Medical Research
-0.28%
Key Executives
Chairman/President/Chief Executive Officer/Director
Mitchell Steiner
Vice Chairman/Director
Harry Fisch
Chief Financial Officer/Chief Administrative Officer
Michele Greco
Chief Scientific Officer
K. Gary Barnette
Independent Director
Mario Eisenberger
Independent Director
Michael Rankowitz
Independent Director
Jesus Socorro
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
03/24/2014
Dividend USD 0.07
04/28/2014
12/16/2013
Dividend USD 0.07
01/27/2014
10/03/2013
Dividend USD 0.07
10/28/2013
07/15/2013
Dividend USD 0.07
07/29/2013
03/27/2013
Dividend USD 0.07
04/29/2013
01/03/2013
Dividend USD 0.06
01/28/2013
10/04/2012
Dividend USD 0.06
10/29/2012
07/13/2012
Dividend USD 0.06
07/30/2012
03/27/2012
Dividend USD 0.06
04/30/2012
01/04/2012
Dividend USD 0.05
01/30/2012
10/06/2011
Dividend USD 0.05
10/31/2011
07/14/2011
Dividend USD 0.05
07/29/2011
04/11/2011
Dividend USD 0.05
04/29/2011
01/14/2011
Dividend USD 0.05
01/27/2011
10/08/2010
Dividend USD 0.05
11/01/2010
07/22/2010
Dividend USD 0.05
08/02/2010
--
Dividend USD 0.05
04/21/2010
01/14/2010
Dividend USD 0.05
01/27/2010
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About VERU
Veru Inc. is an oncology and urology biopharmaceutical company developing medicines for prostate cancer treatment and prostate cancer supportive care, as well as urology specialty pharmaceuticals. Its oncology drug candidates include VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a Phase II clinical trial for the treatment of hot flashes in men, and VERU-100, which is a gonadotropin-releasing hormone (GnRH) antagonist. Its urology specialty pharmaceutical drug candidate is Tadalafil and Finasteride Combination (TADFIN), which is a tadalafil and finasteride combination oral capsule for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal Condom for prevention of pregnancy and sexually transmitted infections, and PREBOOST wipes for the prevention of premature ejaculation.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Veru Inc stock information, including NASDAQ:VERU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VERU stock methods without spending real money on the virtual paper trading platform.